J. Goldman & CO LP Protagonist Therapeutics, Inc Transaction History

J. Goldman & CO LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $578,023 - $2.09 Million	-81,873 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $1.14 Million - $1.76 Million	-48,644 Reduced 37.27%	81,873 $1.94 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $2.3 Million - $4.84 Million	130,517 New	130,517 $4.46 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $258,818 - $993,104	-19,986 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $756,693 - $1.33 Million	-29,593 Reduced 59.69%	19,986 $897,000
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $213,746 - $350,063	11,238 Added 29.31%	49,579 $1.28 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $279,661 - $380,091	15,125 Added 65.15%	38,341 $773,000
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $397,112 - $585,603	-26,143 Reduced 52.97%	23,216 $454,000
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $305,532 - $929,923	49,359 New	49,359 $872,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.